Alchemical analysis of FDA approved drugs.

Orsi, Markus; Probst, Daniel; Schwaller, Philippe; Reymond, Jean-Louis (2023). Alchemical analysis of FDA approved drugs. Digital discovery, 2(5), pp. 1289-1296. Royal Society of Chemistry 10.1039/d3dd00039g

Preview

Text d3dd00039g.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

Chemical space maps help visualize similarities within molecular sets. However, there are many different molecular similarity measures resulting in a confusing number of possible comparisons. To overcome this limitation, we exploit the fact that tools designed for reaction informatics also work for alchemical processes that do not obey Lavoisier's principle, such as the transmutation of lead into gold. We start by using the differential reaction fingerprint (DRFP) to create tree-maps (TMAPs) representing the chemical space of pairs of drugs selected as being similar according to various molecular fingerprints. We then use the Transformer-based RXNMapper model to understand structural relationships between drugs, and its confidence score to distinguish between pairs related by chemically feasible transformations and pairs related by alchemical transmutations. This analysis reveals a diversity of structural similarity relationships that are otherwise difficult to analyze simultaneously. We exemplify this approach by visualizing FDA-approved drugs, EGFR inhibitors, and polymyxin B analogs.

Interest & Impact

Downloads

0 since deposited on 29 Nov 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item